Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CARANYSE:NNVCNASDAQ:TENXNASDAQ:XTLB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4125,274 shs237,144 shsNNVCNanoViricides$1.51$1.38$0.94▼$2.77$24.27M0.91241,917 shs304,213 shsTENXTenax Therapeutics$5.72-2.3%$5.76$2.77▼$7.89$23.71M1.61159,140 shs10,786 shsXTLBXTL Biopharmaceuticals$1.28+13.3%$3.99$0.92▼$3.05$6.16M1.1318,952 shsN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics0.00%0.00%0.00%+3.70%-34.76%NNVCNanoViricides-0.66%+1.34%+20.80%+22.76%-38.37%TENXTenax Therapeutics+1.39%-0.51%+3.17%-8.74%+78.35%XTLBXTL Biopharmaceuticals-0.42%+3.93%-9.85%-3.25%-44.65%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCARACara Therapeutics1.4908 of 5 stars3.00.00.04.20.60.80.0NNVCNanoViricides0.1289 of 5 stars0.03.00.00.01.10.00.0TENXTenax Therapeutics1.6717 of 5 stars3.60.00.00.03.30.00.6XTLBXTL Biopharmaceuticals0.1847 of 5 stars0.03.00.00.00.01.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARACara Therapeutics 0.00N/AN/AN/ANNVCNanoViricides 0.00N/AN/AN/ATENXTenax Therapeutics 3.25Buy$17.50206.21% UpsideXTLBXTL Biopharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest XTLB, NNVC, CARA, and TENX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025TENXTenax TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00NNVCNanoViricidesN/AN/AN/AN/A$0.66 per shareN/ATENXTenax TherapeuticsN/AN/AN/AN/A$27.15 per shareN/AXTLBXTL BiopharmaceuticalsN/AN/AN/AN/A$0.41 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/ANNVCNanoViricides-$8.29M-$0.70N/A∞N/AN/A-87.90%-78.69%N/ATENXTenax Therapeutics-$7.71M-$2.48N/AN/AN/AN/A-46.00%-42.65%8/12/2025 (Estimated)XTLBXTL Biopharmaceuticals-$1.78MN/A0.00∞N/AN/AN/AN/AN/ALatest XTLB, NNVC, CARA, and TENX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025TENXTenax Therapeutics-$0.48-$0.28+$0.20-$0.28N/AN/A3/25/2025Q4 2024TENXTenax Therapeutics-$0.52-$0.18+$0.34-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARACara TherapeuticsN/AN/AN/AN/AN/ANNVCNanoViricidesN/AN/AN/AN/AN/ATENXTenax TherapeuticsN/AN/AN/AN/AN/AXTLBXTL BiopharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARACara TherapeuticsN/A4.774.71NNVCNanoViricidesN/A3.442.47TENXTenax TherapeuticsN/A38.9538.95XTLBXTL BiopharmaceuticalsN/A0.81N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARACara Therapeutics44.66%NNVCNanoViricides10.30%TENXTenax Therapeutics1.67%XTLBXTL Biopharmaceuticals4.40%Insider OwnershipCompanyInsider OwnershipCARACara Therapeutics3.10%NNVCNanoViricides4.60%TENXTenax Therapeutics3.70%XTLBXTL Biopharmaceuticals29.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCARACara Therapeutics804.57 million4.43 millionOptionableNNVCNanoViricides2016.07 million14.92 millionOptionableTENXTenax Therapeutics94.15 million3.28 millionNot OptionableXTLBXTL BiopharmaceuticalsN/A5.45 million3.87 millionNot OptionableXTLB, NNVC, CARA, and TENX HeadlinesRecent News About These CompaniesXTL Biopharmaceuticals names Noam Band as CEOApril 9, 2025 | uk.investing.comXTL Biopharmaceuticals Ltd.: XTL Names Mr. Noam Band as its New Chief Executive OfficerApril 8, 2025 | finanznachrichten.deXTL Biopharmaceuticals Appoints Noam Band as CEOApril 7, 2025 | tipranks.comXTL Names Mr. Noam Band as its New Chief Executive OfficerApril 7, 2025 | globenewswire.comXTL Biopharmaceuticals Reports Financial Results Amid Regional UnrestDecember 30, 2024 | tipranks.comXTL Biopharmaceuticals Expands Portfolio with Social Proxy Acquisition Amidst Regional ChallengesDecember 30, 2024 | tipranks.comXTL Biopharmaceuticals (NASDAQ:XTLB) Stock, Short Interest ReportNovember 5, 2024 | benzinga.comXTL Biopharmaceuticals Ltd (XTLB)September 5, 2024 | investing.comXTL Biopharmaceuticals Ltd XTLBAugust 22, 2024 | morningstar.comXTL Biopharmaceuticals acquires AI firm Social ProxyAugust 16, 2024 | uk.investing.comXTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 MillionAugust 14, 2024 | globenewswire.comXTL Biopharmaceuticals Ltd. (XTLB.TA)July 22, 2024 | finance.yahoo.comXTL Entered Definitive Agreement to Acquire The Social ProxyJune 5, 2024 | globenewswire.comXTL Biopharmaceuticals Ltd. ADRApril 26, 2024 | wsj.comU.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.03%March 20, 2024 | msn.comUS Stocks Edge Lower Ahead Of Fed's Decision; General Mills Earnings Top ViewsMarch 20, 2024 | msn.comDow Surges 350 Points; Fed Holds Rates SteadyMarch 20, 2024 | markets.businessinsider.comCrude Oil Surges 2%; Signet Jewelers Shares Spike HigherMarch 20, 2024 | markets.businessinsider.comXTL To Aquire The Social ProxyMarch 20, 2024 | globenewswire.comXTL Biopharmaceuticals Ltd ADR (XTLB)February 17, 2024 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXTLB, NNVC, CARA, and TENX Company DescriptionsCara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.NanoViricides NYSE:NNVC$1.51 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.50 -0.01 (-0.66%) As of 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.Tenax Therapeutics NASDAQ:TENX$5.72 -0.14 (-2.31%) Closing price 03:59 PM EasternExtended Trading$5.84 +0.13 (+2.19%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.XTL Biopharmaceuticals NASDAQ:XTLBXTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
